Marlio Charles Mosseri, 10% Owner, on June 30, 2026, executed a purchase for 50,000 shares in Nuvectis Pharma (NVCT) for $916,000. Following the Form 4 filing with the SEC, Mosseri has control over a total of 3,295,897 common shares of the company, with 109,321 shares held directly and 3,186,576 controlled indirectly.
SEC Filing:
https://www.sec.gov/Archives/edgar/data/1875558/000110465926079793/xslF345X05/tm2619552-2_4seq1.xml
Price: $19.64, Change: $+1.25, Percent Change: +6.80%
Eugene Schneider, Executive Vice President, Chief Clinical Development Officer, on June 26, 2026, sold 26,000 shares in Ionis Pharmaceuticals (IONS) for $2,107,196. Following the Form 4 filing with the SEC, Schneider has control over a total of 77,114 common shares of the company, with 77,114 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/874015/000087401526000216/xslF345X05/edgardoc.xml
Marcelo Fischer, Chief Financial Officer, on June 26, 2026, sold 23,323 shares in IDT (IDT) for $1,329,024. Following the Form 4 filing with the SEC, Fischer has control over a total of 35,584 Class B common shares of the company, with 32,824 shares held directly and 2,760 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1005731/000119312526290844/xslF345X05/ownership.xml
Nathan Blecharczyk, 10% Owner, Director, Chief Strategy Officer, on June 26, 2026, sold 31,033 shares in Airbnb (ABNB) for $4,544,132. Following the Form 4 filing with the SEC, Blecharczyk has control over a total of 159,231 Class A common shares of the company, with 81,631 shares held directly and 77,600 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1559720/000119312526290807/xslF345X05/ownership.xml